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Association between two CHRNA3 
variants and susceptibility of lung 
cancer: a meta-analysis
Xiao Qu1,*, Kai Wang1,*, Wei Dong2, Hongchang Shen3, Ying Wang1, Qi Liu1 & Jiajun Du1,2
Genome-wide association studies (GWAS) have identified two CHRNA3 polymorphisms (rs578776 and 
rs938682) associated with lung cancer risk. Furthermore, these polymorphisms were investigated and 
genotyped by PCR analysis. All eligible case-control studies published up to Mar 1st 2015 were identified 
by searching Pubmed and Embase database. Negative association between rs578776-T allele and risk 
of lung cancer was obtained without obvious heterogeneity (OR: 0.83, 95% CI: 0.79–0.86; p = 0.898 for 
Q test). Rs938682-C allele carriers had a 12% to 28% decreased risk. Genotype model analysis showed 
results of dominant model for rs578776 (OR with 95% CI: 0.839(0.718–0.981)), dominant model for 
rs938682 (OR with 95% CI: 0.778(0.663–0.912)) and homozygous model for rs938682 (OR with 95% 
CI: 0.767(0.708–0.831)) were statistically significant. Subgroup analysis indicated rs578776-T variant 
had protective effect in Smokers, Caucasians, two histology subgroups, and two match subgroups. 
Meanwhile, rs938682-C allele was associated with decreased risk in Smokers, Caucasians, Lung 
cancer, and two match subgroups. Meta-regression suggested ethnicity might be the major source of 
heterogeneity in allele model and homozygous model for rs938682. Moreover, smoking status might 
contribute to part of heterogeneity under allele model. In summary, this meta-analysis suggested both 
rs578776 and rs938682 were significantly associated with the susceptibility of lung cancer.
Approximately, there are estimated 1.3 billion smokers all over the world1. Epidemiological evidence indicates 
that tobacco smoking can exert its pathogenic effect on almost every organ through direct or indirect tobacco 
exposure, and the smoking associated mortality still remains at a high level for decades2. Tobacco smoking, as 
one of well-known cancer risk factors, was highlighted in the past decades especially for its effect on lung can-
cer3. More than 60 carcinogens could be detected in the tobacco smoke, and they contributed to the procedure 
throughout from nicotine addiction to lung cancer4. Nicotine, as a functional components in the tobacco smoke, 
could promote tumor cells proliferation, metastasis and inhibit apoptosis through binding to nicotinic acetylcho-
line receptors (nAChRs) and β -adrenergic receptors (β -ARs), but not initiate tumor genesis5. What’s more, the 
nicotine derivatives 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosonor nicotine (NNN) 
in the tobacco smoke can also bind to nAChRs and strongly induce carcinogenesis5. That indicates the genes 
encoding nAChRs may be associated with susceptibility of lung cancer.
In 2008, three Genome-wide association studies (GWAS) revealed that CHRNA5-A3 cluster situated on chro-
mosome 15q24-25.1 might be potential loci relevant to both nicotine dependence and smoking related can-
cer6–8. From then on, numerous studies have suggested CHRNA3 gene polymorphisms are associated with many 
types of cancers detection and treatment including lung cancer, gastric cancer, esophageal cancer9–11, etc. Other 
meta-analysis indicated rs105173012, rs649530913, rs12914385, rs804237414 in CHRNA3 were associated with 
lung cancer risk and part of them even had racial difference. Saccone15 proposed the evidence that rs578776 
(C > T) could reduce risk of lung cancer in his meta-analysis (OR: 0.82; p value: 9.74E-10) involving 5 databases 
before 2010. Thereafter, there were several researches in the relation between rs578776 and susceptibility of lung 
cancer. So far, there has been no meta-analysis focusing the association between rs938682 and risk of lung cancer.
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However, the association between both CHRNA3 single nucleotide polymorphisms (SNP, rs578776, 
rs938682) and susceptibility of lung cancer remains inconsistent. To improve statistical power, we conducted the 
meta-analysis based on case-control studies to assess the effect of two SNPs on the susceptibility of lung cancer.
Materials and Methods
Search strategy. PUBMED and EMBASE database were searched by two co-authors separately before 
March 1st 2015 using combinations of following terms: (CHRNA3 OR CHRNA5-3 cluster OR CHRNA3-
CHRNA5-CHRNB4 cluster OR rs578776 OR rs938682 OR 15q25) AND (lung carcinoma OR lung cancer OR 
lung neoplasm) AND (allele OR genotype OR gene OR polymorphism OR mutation OR variant). The title and 
abstract of each potential paper was reviewed by two co-authors independently and any irrelevant one was 
excluded. Process map for the searching details was presented in Fig. 1 under the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement16.
Inclusion and exclusion criteria. Articles which met the following criteria were included in this 
meta-analysis: 1) case-control studies focusing on the association between rs578776, rs938682 and susceptibility 
of lung cancer; 2) providing the odds risk (OR) and its 95% confidence interval (95% CI) of allele or genotype, or 
sufficient information to calculate them; 3) Human study and Full-length articles in English. Reasons for exclu-
sion were: 1) no sufficient data; 2) same cohort or duplicated case/control groups; 3) twin or family based studies.
Data extraction. Data was extracted by two co-authors separately and any difference was dissolved by dis-
cussion participated in by more than two authors. Information extracted were: last name of the first author; pub-
lished year; histology; study design; case and control match; country and ethnicity; smoking status; sample size, 
gender and age information; frequency, OR and 95% CI of allele and genotype. Data was not presented in primary 
publication was marked ‘not applicable (NA)’.
Quality assessment. We assessed the quality of included studies by using a quality score called 
‘Extended-Quality Score’ to limit the bias in the meta-analysis. As the primary designers classify the studies 
into ‘high, median, or poor’ quality, the quality of our included studies was assessed all above 5 points score. The 
details of this quality assessment version were previous described by Li, et al.17.
Statistical analysis. Odds risk (OR) with associated 95% confidence interval (CI) was used to assess the 
association strength. The pooled OR were calculated for estimating the outcome of five genetic models: Allele 
model, heterozygous model, homozygous mode, dominant model and recessive model. Z test was applied to 
test the significance of pooled OR and value of p less than 0.05 was considered as significant. Between-study 
heterogeneity was calculated through Cochran’s chi-square-based Q statistic test and assessed by value of incon-
sistency index (I2 ranging from 0 to 100%)18 whose high value was considered as high heterogeneity. 25%, 50% 
and 75% were assigned to define low, moderate and high heterogeneity18. Pooled ORs were calculated according 
to DerSimonian-Laird Method which took the between-study variation into the calculation19,20. Funnel plot was 
conducted to estimate the potential publication bias. Obvious asymmetric plot reflects publication bias. Egger’s 
linear regression test was conducted to assess the funnel plot asymmetry and its intercept was determined by 
the t-test. A less than 0.05 p value of Egger’s test suggested the existence of potential publication bias. Sensitivity 
Figure 1. The PRISMA processing map. 10 articles were finally included in the meta-analysis.
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analysis and subgroup analysis were feasible methods to find out potential origin of heterogeneity. Subgroups 
included smoking status, ethnicity, histology and match subgroups. Histology referred to NSCLC and lung cancer 
(including NSCLC and other pathology subtypes) subgroups. What’s more, we also conducted another method 
Galbraith plot to test the heterogeneity as a supplement. And points representing researches exceed upper and 
lower confidence interval regression lines may be potential sources of heterogeneity. Meta-regression was applied 
to detect the potential heterogeneity among studies. All p values were two sides and less than 0.05 were consid-
ered significant. STATA software (Stata Corp, Texas, USA, version 12.0 for Windows) was used to perform this 
meta-analysis.
Results
Details of the screening procedure was shown in Fig. 1. After the duplicate removal, the initial 158 articles 
reduced to 133. The top three excluding reasons were other SNPs (n = 47); meta-analysis and review (n = 18); 
cell molecular experiment (n = 15). Finally 10 eligible articles in different cases/control groups met the inclu-
sion criteria to evaluate the association two SNPs rs578776, rs938682 in CHRNA3 gene with susceptibility of 
lung cancer21–30. Additionally, we included the data from Saccone’s article15 for there were no published articles 
reported the impact of rs578776 on lung cancer from these databases except Tseng’s research. Data of Tseng’s 
research came from a part of EAGLE database30. For the polymorphism rs578776, 6 researches and 5 databases 
were included with total 11763 cases and 12574 controls (Caucasian 11115 cases and 11763 controls). For the 
polymorphism rs938682, 6 articles involved a total of 6552 cases and 8085 controls (Caucasian cases/controls: 
5824/7267; Chinese: 728/818). Genotype for control groups in all articles was informed in the Hardy-Weinberg 
Equilibrium (p > 0.05). Basic characteristics of all studies were provided in Table 1.
Impact of rs578776 on the susceptibility of lung cancer. Overall comparison of rs578776-T allele 
yielded a remarkably protective effect for lung cancer (pooled OR: 0.83; 95% CI: 0.79–0.86) compared with 
rs578776-C allele. Meanwhile, there were no evidence of between-study heterogeneity (I2 = 0%, p = 0.898, Fig. 2).
Of all studies, the genotype information was available in Li, Tekpli and Sakoda’s articles (Table 2). The included 
three articles for genotype analysis combined 1256 lung cancer cases and 2025 controls. Significantly reduced 
lung cancer risk was shown under TT + CT versus CC model (OR: 0.839, 95% CI: 0.718–0.981, p = 0.028) with 
absent between-study heterogeneity (I2 = 0.0%). However, no significant association were detected in the other 
three models (CC + CT versus TT model, p = 0.189; Homozygous model TT versus CC, p = 0.109; Heterozygous 
model CT versus CC, p = 0.066) without obvious between-study heterogeneity (I2 of all three models 0.0%).
Impact of rs938682 on the susceptibility of lung cancer. For the polymorphism rs938682-C allele, 
our meta-analysis gave a pooled OR of 0.80 (95% CI: 0.72–0.88; Z = 4.68, p < 0.001). Moreover, there were evi-
dence of moderate between-study heterogeneity (I2 = 47.9%, p = 0.088) under random effect model (Fig. 2).
Four case-control studies included (Li, Skoda, He and Broderick) yielded a total of 5664 lung cancer cases and 
6438 controls for genotype analysis. However, Broderick reported pooled OR with 95% CI under homozygous 
and heterozygous model, and only pooled OR under dominant and recessive model. Thus both heterozygous 
and homozygous model analysis included Broderick’s research but neither dominant nor recessive model could. 
Significant decreased risks were observed under both dominant model CC + CT versus TT (pooled OR with 
95% CI: 0.778(0.663–0.912), p = 0.002, I2 = 0.0%) and heterozygous model CT versus TT (0.767(0.708–0.831), 
p < 0.01, I2 = 0.0%) without statistical heterogeneity. However, the pooled OR was of edge significance with mod-
erate heterogeneity (OR with 95% CI: 0.724(0.520–1.007), p = 0.055, I2 = 60.8%) under homozygous model CC 
versus TT. However, there were no evidence of the association polymorphism rs928682 with the susceptibility of 
lung cancer (OR with 95% CI: 0.989(0.756–1.296), p = 0.938, I2 = 0.0%) under recessive model TT + CT versus 
CC.
Thus for the analysis of heterogeneity of pooled OR of allele model C versus T and homozygous model CC 
versus TT, we conducted the Galbraith plot (Supplementary Fig. 2) to test the heterogeneity again, furthermore 
sensitivity analysis (Supplementary Fig. 1) and subgroup analysis (Table 3) to find out the potential source. 
Through Galbraith plot, we found all researches might not have significant heterogeneity under allelic model 
and homozygous model. After deleting a single involving study each time, the alteration of pooled OR and het-
erogeneity indicated the potential origin of heterogeneity. Through the sensitivity analysis, we found the Tseng’s 
research and Broderick’s research might be the potential heterogeneity resource of allele and homozygous model 
respectively. After removing Tseng’s research, we found the pooled OR under allele model remained significant 
(OR: 0.79, 95% CI: 0.74–0.84, p < 0.001, I2: 36.7; p = 0.176). However, I2 under homozygous model fell to 0.0% 
accompanied with p value of pooled OR 0.311. It was worth noting that the sample size of Broderick was much 
larger than the sum of the other studies (cases: 4417 versus 1247; controls: 4443 versus 1995). That needs to add 
further relevant studies to verify homozygous model.
Subgroup analysis and meta-regression. To seek for the potential sources of heterogeneity and eval-
uate the impact of polymorphisms on specific subgroups, we performed subgroup analysis on smoking status, 
ethnicity, match and histology (Table 3). Rs578776-T allele could significantly reduce the risk of susceptibility 
of lung cancer in smokers, Caucasians, NSCLC patients, lung cancer patients, match and match not mentioned 
subgroups. Meanwhile, ethnicity subgroup analysis showed that the protective effect of rs938682-C allele on 
Chinese might be not as significant as Caucasians (OR: 0.91, 95% CI: 0.79–1.06 for Chinese; OR: 0.75, 95% CI: 
0.69–0.81 for Caucasians). And for the smoking status subgroup analysis, risk of smokers with allele C occurring 
lung cancer was lower than ones with allele T (OR: 0.74; 95% CI: 0.63–0.86). For the Chinese nonsmokers, allele 
C had no statistically significant effect on susceptibility of lung cancer (OR: 0.92, 95% CI: 0.75–1.13). Moreover, 
the ORs of rs938682-C allele were significantly attenuated in lung cancer, match, and match not mentioned (NA) 
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subgroups. To evaluate the impact of ethnicity on the heterogeneity of rs938682 allele model and homozygous 
model, meta-regression was performed (Fig. 3). Proportions of between-study variance explained by ethnicity 
under allele and homozygous model were 100% and 59.67% respectively. To evaluate the impact of smoking status 
on between-study heterogeneity, we did the meta-regression on all smoking subgroups. Meta-regression showed 
that smoking status contributed to 45.41% heterogeneity (Fig. 3).
Publication bias. Publication bias analysis was shown in Fig. 2 in the form of funnel plot. No significant 
publication bias was seen in any funnel plot. All researches included were within the pseudo 95% CI limits in 
funnel plot of three SNPs and showed no significantly asymmetrical. Egger’s test to provide statistical verification 
of publication bias indicated no evidence of publication bias (p = 0.334 for rs578776 rs578776-T allele model and 
p = 0.167 for rs938682-C allele model).
Author Year Histology Design Match Country & ethnicity Smoking status
Published Articles
 Li 2012 NSCLC Hospital Not mentioned China, Asian Nonsmokers only
 Tekpli 2013 NSCLC Hospital pack-years Norway, Caucasian Nonsmokers/Smokers
 Hansen 2010 lung cancer population age, gender and race America, African Nonsmokers/Smokers
 Tseng 2014 ADC population age, gender Italy, Caucasian smokers only
 Timofeeva 2011 lung cancer population center, gender, etc Europe, Caucasian Nonsmokers/Smokers
 Sakoda 2011 lung cancer population age, sex, race, etc non-Hispanic, Caucasian smokers only
 Hung 2008 lung cancer population sex, age, etc Europe, Caucasian Nonsmokers/Smokers
 He 2014 ADC Hospital gender and age China, Asian Nonsmokers/Smokers
 Zhou 2015 lung cancer Hospital Not mentioned China, Asian Nonsmokers/Smokers
 Broderick 2009 lung cancer population Not mentioned U.K, Caucasian Cigarette per day
 Chikova 2012 NSCLC population ethnicity Canada, African Not analyse
 Amos 2010 lung cancer Hospital age, sex, ethnicity America, African Nonsmokers/Smokers
 Lou 2014 NSCLC Hospital age China, Asian Nonsmokers/Smokers
Data from Saccone’s article
 CPS-II-LCA 2010 lung cancer population age, gender, etc America, Caucasian smokers
 MD Anderson 2010 NSCLC Hospital age, gener, race, etc America, Caucasian smokers
 NCI-EAGLE 2010 lung cancer population Not mentioned Italy, Caucasian smokers
 NCI-PLCO 2010 lung cancer population Not mentioned America, Caucasian smokers
 UK-Phase-II 2010 lung cancer population Not mentioned U.K, Caucasian smokers
Author
Number Males percent Mean age rs578776 T rs938682 C rs8040868 C
case control case control case control case control case control case control
Published Articles
 Li 200 200 67.5 62 57.64 56.66 75.6 77.4 41.2 42.2
 Tekpli 310 348 68.7 77.6 66 60 22.5 26.1
 Hansen 448 611 45.8 45.7 64.1 64.6 49.4 53 34.4 32.5
 Tseng 661 1347 79.7 84.9 H H 27 NA 23 NA
 Timofeeva 894 1805 62.2 61.9 H H 27 NA
 Sakoda 746 1477 67.3 66.6 H H 24.5 27.2 19.3 22.6
 Hung 1989 2625 NA NA NA NA NA NA
 He 301 318 49 49 59.6 56.1 43 46
 Zhou 228 301 78.1 62.5 58.7 50.2 41.2 45.6 34.2 37.4
 Broderick 4417 4443 NA NA NA NA NA NA
 Chikova 340 435 59 49 70 40 48 39
 Amos 467 388 54.8 41.2 62.4 55.7 39 32.2
 Lou 500 500 70 51.8 NA NA 35.9 35
Data from Saccone’s article
 CPS-II-LCA 699 748
 MD Anderson 1154 1137
 NCI-EAGLE 1770 1340
 NCI-PLCO 1253 1350
 UK-Phase-II 2300 933
Table 1.  basic information extracted from each study. H: hierarchy; ADC: adenocarcinoma; NSCLC: non-
small cell lung cancer; NA: Not applicable.
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Impact of rs8040868 on the susceptibility of lung cancer. Additionally when screening the pub-
lished GWAS researches including CHRNA3 gene, we found another independent locus rs8040868 (C > T) 
might be related to risk of lung cancer. The searching strategy was the same to strategy reported in method part 
(processing map not shown). Ultimately 1983 cases and 2235 controls for testing rs8040848 were included in 
5 articles22,29,31–33. The basic information was shown in Table 1. The rs8040868-T variant might be related to 
higher susceptibility of lung cancer (OR: 1.17, 95% CI: 1.02–1.33, Z: 2.26, p = 0.024). I2 reflected the existence of 
moderate heterogeneity (I2 = 49.6%) and p value was 0.094. Forest plot and funnel plot were shown in supple-
mentary Fig. 3. Funnel plot of the rs8040868 genetic model seemed symmetrical and cooperation with Egger’s test 
indicated no publication bias (p = 0.783 for rs8040868-T allele model).
Discussion
To our knowledge, this is the first meta-analysis evaluating the association between rs938682 and lung can-
cer susceptibility. As a whole, we found these SNPs (rs578776, rs938682) could reduce the risk of lung cancer 
Figure 2. Forest plots of the association between each mutant allele and susceptibility of lung cancer. 
For each SNP, the mutant allele could decrease (rs578776 and rs938682) the risk of lung cancer without high 
heterogeneity (Fig. 2A, OR: 0.83, 95% CI: 0.79–0.86, I2 = 0.0% for rs578776; Fig. 2C, OR: 0.80, 95% CI: 0.72–
0.88, I2 = 47.9% for rs938682). Funnel plot for publication bias of two SNPs (rs578776, rs938682). Figure 2B,D 
showed all researches seemed no obvious asymmetry and had no significant publication bias. P values of Egger’s 
test for these two SNP were 0.334 and 0.167 respectively.
SNP Genotype Studies OR(95% CI) Z p value I2(%)
rs578776
TT + CTvsCC 3 0.839(0.718–0.981) 2.20 0.028 0.0
CC + CTvsTT 3 1.190(0.918–1.542) 1.31 0.189 0.0
TTvsCC 3 0.768(0.557–1.061) 1.60 0.109 0.0
CTvsCC 3 0.858(0.729–1.010) 1.84 0.066 0.0
rs938682
CC + CTvsTT 3* 0.778(0.663–0.912) 3.10 0.002 0.0
TT + CTvsCC 3* 0.989(0.756–1.296) 0.08 0.938 0.0
CCvsTT 4 0.724(0.520–1.007) 1.92 0.055 60.80
CTvsTT 4 0.767(0.708–0.831) 6.54 < 0.001 0.0
Table 2.  Pooled OR and 95% CI of genotype analysis. *Broderick’s research didn’t report 95% CI of dominant 
model and recessive model, only report value of OR.
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(pooled OR with 95% CI: 0.83(0.79–0.86) for 578776; 0.80(0.72–0.88) for rs938682). Although potential sources 
of heterogeneity between researches can’t be easily evaluated or eliminated, we could assume ethnicity and 
smoking status might be sources through the subgroup analysis especially for rs938682. For Chinese, the asso-
ciation between rs938682 and susceptibility may not be significant (OR: 0.91; 95% CI: 0.79–1.06; p = 0.228). 
However, the remarkable significance can be detected in the results of GWAS from Caucasians (OR: 0.75; 95% 
CI: 0.69–0.81; p < 0.001). Through meta-regression, we evaluated the contribution of ethnicity to heterogeneity. 
Meta-regression indicated that ethnicity contributed to 100% heterogeneity of rs938682 allele model and 59.67% 
heterogeneity of rs938682 homozygous model. Meanwhile we observe that difference in the association of SNP 
rs938682 with lung cancer risk may exist in not only ethnicity but also smoking status subgroups. We calcu-
lated the total HR and 95% CI in smokers and nonsmokers, and found significance in smokers (HR: 0.74; 95% 
CI: 0.63–0.86; p < 0.001) and no significance in nonsmokers (HR: 0.92; 95% CI: 0.75–1.13; p = 0.417). However, 
the nonsmokers were all Asians. To analyze the effect of smoking status and ethnicity on heterogeneity sep-
arately, we further did the meta-regression. For overall studies, ethnicity contributed to 100% heterogeneity. 
For all smoking status subgroups, smoking status contributed to part of heterogeneity (45.41%). That indicated 
that both ethnicity and smoking status influence the association rs938682-C allele with susceptibility of lung 
cancer. Additionally when performing the subgroup analysis of histology, we found that heterogeneity within 
Adenocarcinoma group as a possible result of ethnicity (I-square = 70.9%, p = 0.032 for Q test, data not shown).
After identifying the impact of chromosome 15q25.1 and CHRNA3 gene on the susceptibility of lung cancer 
by three GWAS in 20086–8, further GWAS and meta-analysis revealed many CHRNA3 polymorphisms relevant to 
lung cancer. However, rare meta-analysis focused on protective variants. Apart from the risk SNPs, protective var-
iants possess the same importance for cancer screening. What’s more, the mechanism of the association rs578776 
and rs938682 with susceptibility of lung cancer was well developed through researches in Vivo and Vitro.
CHRNA3 encoding α 3 nAChR submit was reported related to cell apoptosis and depleting or restoring its 
expression could induce or resist cell apoptosis34. And CHRNA3 may be of vital importance to small cell lung 
cancer (SCLC) cell viability and play a direct role in lung cancer susceptibility35. CHRNA3 polymorphism may 
contribute to the cancer occurrence through two feasible mechanisms: direct or nicotine dependent cancer pro-
motion. Tseng, et al.30 reported rs578776 and rs938682 had both direct and total effect on lung adenocarcinoma. 
What’s more, he drew a conclusion through mediation analysis that there were correlations among nicotine 
dependence, lung adenocarcinoma and SNPs.
For the reason that nAChRs play a vital role in nervous system and nicotine conduction pathway, recent 
researches revealed that polymorphisms rs578776 and rs938682 were relevant to neuropsychiatric disease, nic-
otine addiction and lung cancer36–38. Thus the association two polymorphisms with lung cancer might result 
from direct genetic susceptibility and indirect smoking carcinogenesis. Recent researches put emphasis on the 
association between rs578776 and smoking behavior in different countries and ethnic groups39,40. A meta-analysis 
indicated that rs578776 was relevant to age of first regular tobacco use41. rs578776 may also play a vital role in the 
heaviness of smoking and the age of smoking onset41.
However, through the research in rs12914385 and rs8042374 neither rs938682 nor rs578776, Wang, et al. 
emphasized that CHRNA3 might impact indirectly on lung cancer rather than direct effect mainly due to two 
arguments listed below: variants carriers in CHRNA3 SNPs increase CPD (cigarettes per day); for never smokers 
the association between SNPs and lung cancer susceptibility may not be significant42. To better explore the effect 
of nicotine exposure, Timofeeva, et al.28 evaluated the effect of smoking exposure and CHRNA3 gene polymor-
phisms on the lung cancer occurrence through not only smoking amount (CPD and duration) but also smoking 
metabolite cotinine level. And he found rs578776 mutant variant T had protective effect for lung adenocarci-
noma and the minor allele accompanied with decreased cotinine levels. Moreover, this protective effect might 
not be significant for the never smokers. However, Tyndale reported the variant allele in rs578776 was irrelevant 
Subgroups
rs578776 rs938682
Studies OR 95% CI I2(%) p I2 Studies OR 95% CI I2(%) p I2
Smoking
 smokers 8 0.82(0.78–0.87) 1.4 0.419 4 0.74(0.63–0.86) 36.9 0.191
 nonsmokers 2 0.98(0.77–1.24) 0.0 0.494 3 0.92(0.75–1.13) 0.0 0.495
Ethnicity
 East Asian 1 0.91(0.65–1.26) 3 0.91(0.79–1.06) 0.0 0.926
 Caucasian 9 0.82(0.78–0.86) 0.0 0.833 3 0.75(0.69–0.81) 32.3 0.228
 African 1 0.87(0.73–1.03)
Histology
 NSCLC 3 0.83(0.73–0.93) 0.0 0.827 3 0.82(0.65–1.04) 71.3 0.031
 Mixed 8 0.83(0.79–0.87) 0.0 0.719 3 0.78(0.72–0.85) 20.9 0.282
Matched
 Yes 7 0.83(0.78–0.88) 0.0 0.983 3 0.78(0.66–0.92) 61.3 0.076
 NM 4 0.83(0.76–0.90) 21.6 0.281 3 0.83(0.70–0.97) 54.0 0.114
Table 3.  Subgroups analysis of allelic model for rs578776 and rs938682. OR: odds ratio; CI: confidence 
interval; NSCLC: non-small cell lung cancer; NM: not mentioned.
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to CPD but relevant to a lower cotinine level43. Moreover, through altering the dACC–thalamus circuit which 
was reported sensitive to the “status” of smoking rs578776 may influence nicotine dependence through intrinsic 
reward sensitivity deficit for the smokers44,45. Thus rs578776 may contribute to the nicotine dependence. What’s 
more, Wang, et al.46 proposed some new explanation for the relation between SNPs and lung cancer susceptibil-
ity: alteration of nAChRs subunits function and variability in mRNA expression. He reported that rs578776 and 
rs938682 influenced CHRNA5 mRNA expression. And the level of CHRNA5 mRNA was associated with risk of 
nicotine dependence. Thus the effect of these two SNPs on the lung cancer risk may partially play a part through 
this indirect mechanism. Moreover, rs578776 in another research was related to multiple primary cancers even in 
never smokers47. By the subgroup analysis, the rs578776 and rs938682 are both significant in smokers (HR: 0.82 
(0.78–0.87) for rs578776; HR: 0.74 (0.63–0.86) for rs938682).
Although not the emphasis in this meta-analysis, rs8040868 allele T mutation was associated with an 
increased risk of lung cancer (OR: 1.17; 95% CI: 1.02–1.33). The mutation in rs8040868 is a synonymous mutation 
(do not change the encoding amino acids and the reading frame)48; nevertheless, it was reported related to the 
DNA methylation of CHRNB4 and down regulation of CHRNB4 resulted in reduced proliferation and colonies 
formation49.
In summary, these two SNPs (rs578776 and rs938682) may reduce the risk of lung cancer due to the difference 
in central nervous system function and nicotine dependence; nicotine metabolism and exposure; effect on other 
genes expression and function; and direct effect on lung cancer.
However, there are some limitations in our meta-analysis. Firstly, heterogeneity may be the most important 
problem for the distinct baseline information of cases and controls; study design and implement; lab technique; 
statistic processing; paper writing and so on. We spared no effort to minimize the heterogeneity by selecting the 
included paper critically by inclusion and exclusion criteria; extracting and analyzing data strictly by two different 
authors. Secondly, concrete data of three SNPs can’t be obtained from all GWAS and replication studies. Details 
needed to perform subgroup analysis can’t be obtained from all articles. We took full advantage of tables, figures 
and supplementary information to directly extract or indirectly calculate data we need. Thirdly, the amount of 
researches is not enough to sufficiently evaluate the effect of genotype, smoking behavior, gender, age, histology, 
ethnicity, and study design on the association between these three SNPs and susceptibility of lung cancer. Lastly, 
all information was only available in published data. So publication bias, selection bias, or any other potential bias 
may be inevitable.
In summary, rs578776 and rs938682 are related to susceptibility of lung cancer, and variants in these two 
SNPs play a protective role. Rs938682-C allele may be significant in Chinese nonsmokers. And rs578776-T allele 
and rs938682-C allele may be effective for smokers. This research may contribute to screening high risk groups 
in healthy people and have vital significance for Public Health. Moreover, this may predict further onset of lung 
cancer in family with cancer history. More researches may be needed to confirm the association between these 
SNPs with susceptibility of lung cancer and answer new questions whether these SNPs were related to prognosis 
and response to chemotherapy.
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